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Introduction
Osteoporosis is a progressive systemic skeletal disease character-
ized by low bone mass and microarchitectural deterioration
of bone tissue, increasing the risk of low-trauma fractures. Hip
fractures are the most devastating consequences of osteoporosis,
with an increase in mortality, and a loss of independence in daily
living activities in a large proportion of survivors. The con-
sequences of vertebral fractures are now recognized, although the
majority of them do not come to clinical attention at the time they
occur. Recurrent vertebral fractures are responsible for chronic
back pain, thoracic hyperkyphosis, height loss, reduced physical
function and decreased quality of life. Moreover, non-hip, non-
spine fractures—which are the most frequent fractures—are the
greatest cause of disability in people in their sixties.
Thus, beyond the diagnosis of osteoporosis, which is based on
BMD measurement, the objective of osteoporosis management
is the recognition of subjects at high risk for fracture. Prevalent
fractures, including wrist and peripheral fractures, are common
missed opportunities to identify patients at high risk of sustain-
ing subsequent fractures. But other risk factors (family history of
fracture, low BMI, risk of falls, underlying disease, as RA, current
or past use of corticosteroids, etc.) provide relevant information to
identify women who could benefit from a therapeutic intervention.
In the near future, it is highly probable that techniques other than
dual energy X-ray absorptiometry, which assess intrinsic bone
parameters, as micro-architecture and cortical characteristics, will
help physicians to assess fracture risk appropriately and design
therapeutic strategies tailored to individual patients.
Bone is a living tissue, and more and more is known
about determinants of bone remodelling and bone cell activity.
Osteoblast and osteoclast interactions are now well known.
The ‘third cell’—the osteocyte that till now has been neglected—
is likely to have an important role. Of particular interest are the
effects of other cells, as dendritic cells and T lymphocytes, and
their cytokines on bone cell activity. All these topics are under
investigation in the search for keys to controlling bone resorp-
tion and formation. The ideal treatment should improve bone
strength and bone quality, thereby decreasing its propensity to
fracture following minor trauma. Clinical studies have shown
that it is possible to obtain this result by decreasing bone
resorption (bisphosphonates, selective oestrogen receptor mod-
ulators), improving bone formation (parathyroid hormone) or
both (strontium ranelate). In the near future, appropriate treat-
ment sequences must be elaborated to ensure careful treatment
and preservation of bone tissue.
This issue provides updated data on bone structure and bone
assessment, as well as a review of efficacy and safety of strontium
ranelate. It is hoped that this will help clinicians in their own
approach to the management of osteoporotic patients.
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